Sort by

Send to

Choose Destination

Links from PubMed

Items: 7


Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777. Epub 2015 Jan 5.


Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Yang RK, Sondel PM.

Drugs Future. 2010;35(8):665.


Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK; International neuroblastoma Risk Group Task Force.

Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28.


Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Cheung IY, Feng Y, Gerald W, Cheung NK.

Clin Cancer Res. 2008 Nov 1;14(21):7020-7. doi: 10.1158/1078-0432.CCR-08-0541.


Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes.

Deepak S, Kottapalli K, Rakwal R, Oros G, Rangappa K, Iwahashi H, Masuo Y, Agrawal G.

Curr Genomics. 2007 Jun;8(4):234-51.


Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.

Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK.

J Mol Diagn. 2007 Apr;9(2):237-41.

Items per page

Supplemental Content

Support Center